Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Hannah Kopelman, Christina Kontzias, Christopher Alihosseni & Steven R. Feldman. (2023) JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology 19:8, pages 537-542.
Read now
Read now
Aishwarya Muddebihal, Ananta Khurana & Kabir Sardana. (2023) JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. Expert Review of Clinical Pharmacology 16:4, pages 279-295.
Read now
Read now
Jingya Zhang, Fei Qi, Jie Dong, Yaqi Tan, Ling Gao & Fang Liu. (2022) Application of Baricitinib in Dermatology. Journal of Inflammation Research 15, pages 1935-1941.
Read now
Read now
Mohammad I. Fardos, Rohan Singh, Patrick O. Perche, Katherine A. Kelly & Steven R. Feldman. (2022) Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. Expert Review of Clinical Immunology 18:3, pages 221-231.
Read now
Read now
Maddalena Napolitano, Gabriella Fabbrocini, Angelo Ruggiero, Vincenzo Marino, Mariateresa Nocerino & Cataldo Patruno. (2021) The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data. Drug Design, Development and Therapy 15, pages 1135-1147.
Read now
Read now
Guohong Hu & Xiansheng Zhou. (2021) Gallic Acid Ameliorates Atopic Dermatitis-Like Skin Inflammation Through Immune Regulation in a Mouse Model. Clinical, Cosmetic and Investigational Dermatology 14, pages 1675-1683.
Read now
Read now
Milaan A. Shah, Katherine G. Beuerlein, Joseph L. Jorizzo & Steven R. Feldman. (2021) Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?. Journal of Dermatological Treatment 32:7, pages 669-672.
Read now
Read now
Novin Nezamololama, Erika L. Crowley, Melinda J. Gooderham & Kim Papp. (2020) Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opinion on Investigational Drugs 29:9, pages 911-917.
Read now
Read now
Sonja Senner, Marlene Seegräber, Surina Frey, Benjamin Kendziora, Laurie Eicher & Andreas Wollenberg. (2020) Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Review of Clinical Immunology 16:7, pages 641-650.
Read now
Read now
Articles from other publishers (45)
Jinkai Li, Jiawei Duan, Yujiao Wang, Peijie Zhou, Xuan Wang, Ning Xia, Jie Wang, Jia Li, Wenfei Wang, Xiao Wang, Jing Sun, Dongyan Guo, Junbo Zou, Xiaofei Zhang & Changli Wang. (2023) The JAK/STAT/NF-κB signaling pathway can be regulated by rosemary essential oil, thereby providing a potential treatment for DNCB-induced in mice. Biomedicine & Pharmacotherapy 168, pages 115727.
Crossref
Crossref
Gebhard Thoma, Odile Decoret, Eric Vangrevelinghe, Markus Trunzer, Andrea Decker, Anette Orjuela Leon, Christian Beerli, Sandro Bruno, Alice Hauchard, Guido Paulat, Hans-Guenter Zerwes & Feriel Hacini-Rachinel. (2023) Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood. Journal of Medicinal Chemistry 66:21, pages 15042-15053.
Crossref
Crossref
Ana Maria Lé, Melinda Gooderham & Tiago Torres. (2023) Abrocitinib for the treatment of atopic dermatitis. Immunotherapy 15:16, pages 1351-1362.
Crossref
Crossref
Paul Changelian, Canxin Xu, Steve Mnich, Heidi Hope, Kourtney Kostecki, Jeff Hirsch, Chin-Yi Loh, David Anderson, James Blinn, Susan Hockerman, Evan Dick, Walter Smith, Joseph Monahan, Tooraj Raoof, Seth Forman, David Burt, Brad Barnes, David Gordon, Neal Walker, John Sudzina, Stephen Tucker & Jon Jacobsen. (2023) ATI-1777 a topical JAK1/3 inhibitor may benefit atopic dermatitis without systemic drug exposure, results from preclinical development and Phase 2a randomized-control study ATI-1777-AD-201. JID Innovations, pages 100251.
Crossref
Crossref
Ujwala WasnikSameer LakadeMinal HardeMugdha BandukeTrupti DigheAbhijeet MorePrathmesh NaleAjay PatangeShivshankar WaghmareDnyneshwar Kharsade. (2023) Green HPTLC - Densitometric approach for quantitation of Ruxolitinib in bulk and marketed formulation. Research Journal of Pharmacy and Technology, pages 4219-4224.
Crossref
Crossref
Evgeniya A. Shatokhina, Aleksandra S. Polonskaia, Anastasiya Yu. Syryseva, Anna V. Michenko, Maksim N. Shatokhin & Larisa S. Kruglova. (2023) Janus kinase inhibitors efficacy for the treatment of adult atopic dermatitis in real clinical practice. Russian Journal of Allergy 20:2, pages 238-249.
Crossref
Crossref
Gebhard Thoma, Eric Vangrevelinghe, Alexandre Luneau, Philippe Piechon, Christian Beerli & Hans-Guenter Zerwes. (2023) Novel Concept for Super-Soft Topical Drugs: Deactivation by an Enzyme-Induced Switch into an Inactive Conformation. ACS Medicinal Chemistry Letters 14:6, pages 841-845.
Crossref
Crossref
Qin Gao, Yanxia Zhao & Junling Zhang. (2023) Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon 9:6, pages e16704.
Crossref
Crossref
Sara Sadeghi & Nessa Aghazadeh Mohandesi. (2023) Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review. Experimental Dermatology 32:5, pages 599-610.
Crossref
Crossref
O. B. Tamrazova, A. S. Stadnikova, E. A. Glukhova, N. F. Dubovets, A. S. Vorobeva & E. R. Radchenko. (2023) The recurrent course of atopic dermatitis: therapeutic options for management of disease and prolongation of remissions. Meditsinskiy sovet = Medical Council:6, pages 193-200.
Crossref
Crossref
Hidemi Nakagawa, Atsuyuki Igarashi, Hidehisa Saeki, Kenji Kabashima, Tomomi Tamaki, Hironobu Kaino & Yasushi Miwa. (2023) Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergology International.
Crossref
Crossref
Yue Ren, Qi Wu, Chaoqun Liu, Jianing Zhang, Zian Wang, Yingying Li & Yanling Zhang. (2023) Discovery of a traditional Chinese herbal combination for the treatment of atopic dermatitis: saposhnikoviae radix, astragali radix and cnidium monnieri. Archives of Dermatological Research 315:7, pages 1953-1970.
Crossref
Crossref
Gebhard Thoma, Rudolf O. Duthaler, Rudolf Waelchli, Alice Hauchard, Sandro Bruno, Ulrike Strittmatter-Keller, Anette Orjuela Leon, Sabine Viebrock, Reiner Aichholz, Karen Beltz, Kerri Grove, Shaila Hoque, Patrick J. Rudewicz & Hans-Guenter Zerwes. (2023) Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis. Journal of Medicinal Chemistry 66:3, pages 2161-2168.
Crossref
Crossref
Kevin P. Lee, John Plante, Jeffrey E. Korte & Dirk M. Elston. (2022) Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta‐analysis. Skin Health and Disease 3:1.
Crossref
Crossref
Cezmi A. Akdis, Mübeccel Akdis, Scott D. Boyd, Vanitha Sampath, Stephen J. Galli & Kari C. Nadeau. (2023) Allergy: Mechanistic insights into new methods of prevention and therapy. Science Translational Medicine 15:679.
Crossref
Crossref
Ana Maria Lé & Tiago Torres. (2022) OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 14:12, pages 2753.
Crossref
Crossref
Ruchi P. Agashe, Scott M. Lippman & Razelle Kurzrock. (2022) JAK: Not Just Another Kinase. Molecular Cancer Therapeutics 21:12, pages 1757-1764.
Crossref
Crossref
Nali Yang, Lele Chen, Junyi Shao, Fan Jiang, Jingjing Liu & Zhiming Li. (2022) Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab. British Journal of Dermatology 187:5, pages 828-830.
Crossref
Crossref
Bin Wang, Shuaixi Pan, Yue Yao, Linxi Zeng & Guoqiang Zhang. (2022) Efficacy and safety of baricitinib for the treatment of moderate‐to‐severe atopic dermatitis: A systematic review and meta‐analysis of randomized clinical trials. Clinical and Experimental Pharmacology and Physiology 49:11, pages 1139-1149.
Crossref
Crossref
Kazuhiko Yamamura & Takeshi Nakahara. (2022) The Dawn of a New Era in Atopic Dermatitis Treatment. Journal of Clinical Medicine 11:20, pages 6145.
Crossref
Crossref
T. Bieber, A.S. Paller, K. Kabashima, M. Feely, M.J. Rueda, J.A. Ross Terres & A. Wollenberg. (2022) Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. Journal of the European Academy of Dermatology and Venereology 36:9, pages 1432-1449.
Crossref
Crossref
Kamran Ali, Liming Wu, YunMi Qiu & Menghua Li. (2022) Case report: Clinical and histopathological characteristics of psoriasiform erythema and de novo IL-17A cytokines expression on lesioned skin in atopic dermatitis children treated with dupilumab. Frontiers in Medicine 9.
Crossref
Crossref
Elena Galli, Anna Belloni Fortina, Giampaolo Ricci, Nunzia Maiello, Iria Neri, Ermanno Baldo, Irene Berti, Domenico Bonamonte, Lucetta Capra, Elena Carboni, Rossella Carello, Francesca Caroppo, Giovanni Cavagni, Iolanda Chinellato, Francesca Cipriani, Pasquale Comberiati, Andrea Diociaiuti, Vito Di Lernia, Marzia Duse, Cesare Filippeschi, Arianna Giannetti, Mattia Giovannini, Amelia Licari, Gian Luigi Marseglia, Manuela Pace, Annalisa Patrizi, Giovanni Battista Pajno, Diego Peroni, Alberto Villani & Lawrence Eichenfield. (2022) Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Italian Journal of Pediatrics 48:1.
Crossref
Crossref
Velpula Prasannanjaneyulu, Shweta Nene, Harsha Jain, Rimsha Nooreen, Shivam Otavi, Palak Chitlangya & Saurabh Srivastava. (2022) Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis. Cytokine & Growth Factor Reviews 65, pages 12-26.
Crossref
Crossref
Laura Maintz, Thomas Bieber, Helen D. Simpson & Anne-Laure Demessant-Flavigny. (2022) From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine. Journal of Personalized Medicine 12:6, pages 893.
Crossref
Crossref
José Manuel Carrascosa Carrillo, Eulalia Baselga Torres, Yolanda Gilaberte Calzada, Yanina Nancy Jurgens Martínez, Gastón Roustan Gullón, Juan Ignacio Yanguas Bayona, Susana Gómez Castro, Maria Giovanna Ferrario & Francisco José Rebollo Laserna. (2022) Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment. Dermatology and Therapy 12:5, pages 1197-1210.
Crossref
Crossref
Lan Wang, Yan-Fang Xian, Steven King Fan Loo, Siu Po Ip, Wen Yang, Wood Yee Chan, Zhi-Xiu Lin & Justin Che Yuen Wu. (2022) Baicalin ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice through modulating skin barrier function, gut microbiota and JAK/STAT pathway. Bioorganic Chemistry 119, pages 105538.
Crossref
Crossref
Ben Witkoff, Christopher M. Logas, Brad P. Glick & James Q. Del Rosso. (2022) JAK inhibitors in the treatment of atopic dermatitis. Dermatological Reviews 3:1, pages 20-28.
Crossref
Crossref
Wirawan Adikusuma, Lalu Muhammad Irham, Wan-Hsuan Chou, Henry Sung-Ching Wong, Eko Mugiyanto, Jafit Ting, Dyah Aryani Perwitasari, Wei-Pin Chang & Wei-Chiao Chang. (2021) Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Frontiers in Immunology 12.
Crossref
Crossref
Alessio Gambardella, Gaetano Licata, Giulia Calabrese, Alina De Rosa, Roberto Alfano & Giuseppe Argenziano. (2021) Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. Dermatitis 32:1S, pages e85-e86.
Crossref
Crossref
Xiao Xiao Wu, Wing Sum Siu, Chi Ling Wat, Chung Lap Chan, Chi Man Koon, Xiang Li, Wen Cheng, Hui Ma, Miranda Sin Man Tsang, Christopher Wai-Kei Lam, Ping Chung Leung, Clara Bik San Lau & Chun-Kwok Wong. (2021) Effects of topical application of a tri-herb formula on inflammatory dry-skin condition in mice with oxazolone-induced atopic dermatitis. Phytomedicine 91, pages 153691.
Crossref
Crossref
Hidemi Nakagawa, Osamu Nemoto, Atsuyuki Igarashi, Hidehisa Saeki, Kenji Kabashima, Manabu Oda & Takeshi Nagata. (2021) Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Journal of the American Academy of Dermatology 85:4, pages 854-862.
Crossref
Crossref
Jennifer B. Scott & Amy S. Paller. (2021) Novel treatments for pediatric atopic dermatitis. Current Opinion in Pediatrics 33:4, pages 392-401.
Crossref
Crossref
Seok-Young Kang, Ji-Young Um, Bo-Young Chung, Jin-Cheol Kim, Chun-Wook Park & Hye-One Kim. (2021) Differential Diagnosis and Treatment of Itching in Children and Adolescents. Biomedicines 9:8, pages 919.
Crossref
Crossref
Xiaohua Gong, Xuejun Chen, Michael E. Kuligowski, Xing Liu, Xiang Liu, Evan Cimino, Ryan McGee & Swamy Yeleswaram. (2021) Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies. American Journal of Clinical Dermatology 22:4, pages 555-566.
Crossref
Crossref
Franz J. Legat. (2021) Itch in Atopic Dermatitis – What Is New?. Frontiers in Medicine 8.
Crossref
Crossref
Sultan Albuhairi & Rima Rachid. (2021) Biologics and Novel Therapies for Food Allergy. Immunology and Allergy Clinics of North America 41:2, pages 271-283.
Crossref
Crossref
Mi-Ae Kang, Jongsung Lee, Chang Min Lee, Ho Sung Park, Kyu Yun Jang & See-Hyoung Park. (2021) IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway. Journal of Personalized Medicine 11:4, pages 284.
Crossref
Crossref
Laura M. Cobb & Michael R. Verneris. (2021) Therapeutic manipulation of innate lymphoid cells. JCI Insight 6:6.
Crossref
Crossref
Marcella Massimini, Elena Dalle Vedove, Benedetta Bachetti, Francesco Di Pierro, Cataldo Ribecco, Claudio D'Addario & Mariangela Pucci. (2021) Polyphenols and Cannabidiol Modulate Transcriptional Regulation of Th1/Th2 Inflammatory Genes Related to Canine Atopic Dermatitis. Frontiers in Veterinary Science 8.
Crossref
Crossref
Kazuhisa Furue, Takamichi Ito, Gaku Tsuji, Dugarmaa Ulzii, Yen Hai Vu, Makiko Kido‐Nakahara, Takeshi Nakahara & Masutaka Furue. (2019)
The
IL
‐13–
OVOL
1–
FLG
axis in atopic dermatitis
. Immunology 158:4, pages 281-286.
Crossref
Crossref
Hidemi Nakagawa, Osamu Nemoto, Atsuyuki Igarashi, Hidehisa Saeki, Manabu Oda, Kenji Kabashima & Takeshi Nagata. (2019) Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. Journal of Allergy and Clinical Immunology 144:6, pages 1575-1583.
Crossref
Crossref
Ana M. Montilla, Francisco Gómez-García, Pedro J. Gómez-Arias, Jesús Gay-Mimbrera, Jorge Hernández-Parada, Beatriz Isla-Tejera & Juan Ruano. (2019) Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. Dermatology and Therapy 9:4, pages 655-683.
Crossref
Crossref
Galina I. Smirnova & A. A. Korsunsky. (2019) DISORDERS OF SKIN MICROBIOTA AND FORMATION OF ATOPIC DERMATITIS IN CHILDREN. Russian Pediatric Journal 22:4, pages 243-250.
Crossref
Crossref
Özgür Gündüz. (2019) JAK/STAT pathway modulation: Does it work in dermatology?. Dermatologic Therapy 32:3.
Crossref
Crossref